Literature DB >> 31471727

Resistant Hypertension Updated Guidelines.

Irene Chernova1, Namrata Krishnan2,3.   

Abstract

PURPOSE OF REVIEW: To discuss the current definition as well as recommendations for diagnosis and treatment of resistant hypertension (RH) based on the 2018 American Heart Association (AHA) guidelines and recent literature. RECENT
FINDINGS: RH is defined as uncontrolled blood pressure (BP) on ≥ 3 anti-hypertensives, one of which should be a diuretic, prescribed at maximally tolerated doses and appropriate dosing frequency. The diagnosis of RH requires exclusion of white coat effect and medication non-adherence, underscoring the importance of out-of-office BP measurements. Secondary causes of hypertension must be excluded in all patients with RH. A step-wise approach to treatment focusing on lifestyle modifications and medication optimization can be effective in > 50% of the patients with RH. Device-based interventional therapies for RH are currently investigational. Out-of-office BP measurements are central to the diagnosis of RH. Medication optimization is successful in most patients. Further studies are needed to define the role of device-based interventions.

Entities:  

Keywords:  Ambulatory BP monitoring; Hyperaldosteronism; Pseudoresistance; Renal denervation; Resistant hypertension; White coat hypertension

Year:  2019        PMID: 31471727     DOI: 10.1007/s11886-019-1209-6

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  98 in total

1.  Hyperaldosteronism among black and white subjects with resistant hypertension.

Authors:  David A Calhoun; Mari K Nishizaka; Mohammad A Zaman; Roopal B Thakkar; Paula Weissmann
Journal:  Hypertension       Date:  2002-12       Impact factor: 10.190

2.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

Authors:  Anne L Taylor; Susan Ziesche; Clyde Yancy; Peter Carson; Ralph D'Agostino; Keith Ferdinand; Malcolm Taylor; Kirkwood Adams; Michael Sabolinski; Manuel Worcel; Jay N Cohn
Journal:  N Engl J Med       Date:  2004-11-08       Impact factor: 91.245

3.  Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale.

Authors:  M T Kim; M N Hill; L R Bone; D M Levine
Journal:  Prog Cardiovasc Nurs       Date:  2000

4.  Resistant hypertension: comparing hemodynamic management to specialist care.

Authors:  Sandra J Taler; Stephen C Textor; Jo Ellen Augustine
Journal:  Hypertension       Date:  2002-05       Impact factor: 10.190

5.  Effects of insufficient sleep on blood pressure in hypertensive patients: a 24-h study.

Authors:  P Lusardi; A Zoppi; P Preti; R M Pesce; E Piazza; R Fogari
Journal:  Am J Hypertens       Date:  1999-01       Impact factor: 2.689

6.  Primary aldosteronism--careful investigation is essential and rewarding.

Authors:  Michael Stowasser; Richard D Gordon
Journal:  Mol Cell Endocrinol       Date:  2004-03-31       Impact factor: 4.102

7.  Efficacy of low-dose spironolactone in subjects with resistant hypertension.

Authors:  Mari Konishi Nishizaka; Mohammad Amin Zaman; David A Calhoun
Journal:  Am J Hypertens       Date:  2003-11       Impact factor: 2.689

8.  High prevalence of secondary hypertension and insulin resistance in patients with refractory hypertension.

Authors:  Nieves Martell; Matilde Rodriguez-Cerrillo; D E Grobbee; M Dolores López-Eady; Carmen Fernández-Pinilla; Mario Avila; Arturo Fernández-Cruz; Manuel Luque
Journal:  Blood Press       Date:  2003       Impact factor: 2.835

9.  Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region.

Authors:  B Strauch; T Zelinka; M Hampf; R Bernhardt; J Widimsky
Journal:  J Hum Hypertens       Date:  2003-05       Impact factor: 3.012

10.  Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women.

Authors:  Jaqueline Neves Lubianca; Carlo Sasso Faccin; Flávio Danni Fuchs
Journal:  Contraception       Date:  2003-01       Impact factor: 3.375

View more
  3 in total

Review 1.  Implant-Mediated Therapy of Arterial Hypertension.

Authors:  Mortimer Gierthmuehlen; Dennis T T Plachta; Josef Zentner
Journal:  Curr Hypertens Rep       Date:  2020-02-06       Impact factor: 5.369

2.  Clinical outcomes of laparoscopic-based renal denervation plus adrenalectomy vs adrenalectomy alone for treating resistant hypertension caused by unilateral aldosterone-producing adenoma.

Authors:  Yahui Liu; Binbin Zhu; Lijie Zhu; Linwei Zhao; Degang Ding; Zhonghua Liu; Zhiqiang Fan; Qiuping Zhao; You Zhang; Jiguang Wang; Chuanyu Gao
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-18       Impact factor: 3.738

3.  Network Pharmacology Prediction and Pharmacological Verification Mechanism of Yeju Jiangya Decoction on Hypertension.

Authors:  Ting Wang; Mao He; Yuzhong Du; Suhong Chen; Guiyuan Lv
Journal:  Evid Based Complement Alternat Med       Date:  2021-05-10       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.